Helsinn Entered into an Exclusive License and Distribution Agreement with Immedica to Commercialize Akynzeo and Aloxi
- The companies collaborated to commercialize two cancer supportive care products i.e., Akynzeo (netupitant-palonosetron fixed combination) and Aloxi (palonosetron) for the prevention of CT-induced nausea and vomiting in core EU markets
- Immedica will be responsible to commercialise Akynzeo in Portugal, Spain, France, Switzerland, the Netherlands, Belgium, Luxembourg & Liechtenstein while ALOXI in Switzerland, Belgium, Liechtenstein
- Akynzeo is the first 5-HT3 and NK1 receptor antagonist fixed combination & Aloxi has been approved in the EU for the same indication. Akynzeo & Aloxi is currently available in 60+ & 40+ countries, respectively
Ref: Globenewswire | Image: Helsinn
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.